Search

Your search keyword '"Heudel, P-E"' showing total 39 results
Start Over Author "Heudel, P-E"
39 results on '"Heudel, P-E"'

2. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Author

Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., Heudel, P.-E., Bonneville-Levard, A., Fléchon, A., Sarabi, M., Guibert, P., Bachelot, T., Pérol, M., You, B., Bonnin, N., Collard, O., Leyronnas, C., Attignon, V., Baudet, C., Sohier, E., Villemin, J.-P., Viari, A., Boyault, S., Lantuejoul, S., Paindavoine, S., Treillleux, I., Rodriguez, C., Agrapart, V., Corset, V., Garin, G., Chabaud, S., Pérol, D., and Blay, J.-Y.

Published
2019
Full Text
View/download PDF

4. 815P Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study

Author

Alexandre, J., primary, Boudier, P., additional, Kalbacher, E., additional, Asselain, B., additional, Lavit, E., additional, Emambux, S., additional, Berton-Rigaud, D., additional, Babin, G., additional, Lescure, C., additional, Heudel, P-E., additional, Salaun, H., additional, Delanoy, N., additional, Dawood, H., additional, Combe, P-F., additional, Duliege, D., additional, Selle, F., additional, Hakme, A., additional, Cagnan, L., additional, Niogret, J., additional, and De Percin, S., additional

Published
2023
Full Text
View/download PDF

7. LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

Author

Kurtz, J.E., primary, Pujade-Lauraine, E., additional, Oaknin, A., additional, Belin, L., additional, Tsibulak, I., additional, Cibula, D., additional, Vergote, I.B., additional, Rosengarten, O.S., additional, Rodrigues, M.J., additional, de Gregorio, N., additional, Martinez-Garcia, J., additional, Pautier, P., additional, Mouret Reynier, M.A., additional, Selle, F., additional, D'Hondt, V., additional, Lobbedez, F. Joly, additional, Boissier, E. Bultot, additional, Floquet, A., additional, Heudel, P-E., additional, and Heitz, F., additional

Published
2022
Full Text
View/download PDF

9. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

Author

Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P. E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A. C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., NʼKodia, A., Gilles-Afchain, L., Morre, M., Pérol, D., Blay, J. Y., and Caux, C.

Published
2015
Full Text
View/download PDF

13. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women.

Author

Cairat, M, Al Rahmoun, M, Gunter, MJ, Heudel, P-E, Severi, G, Dossus, L, Fournier, A, Cairat, M, Al Rahmoun, M, Gunter, MJ, Heudel, P-E, Severi, G, Dossus, L, and Fournier, A

Abstract

BACKGROUND: Glucocorticoids could theoretically decrease breast cancer risk through their anti-inflammatory effects or increase risk through immunosuppression. However, epidemiological evidence is limited regarding the associations between glucocorticoid use and breast cancer risk. METHODS: We investigated the association between systemic glucocorticoid use and breast cancer incidence in the E3N cohort, which includes 98,995 women with information on various characteristics collected from repeated questionnaires complemented with drug reimbursement data available from 2004. Women with at least two reimbursements of systemic glucocorticoids in any previous 3-month period since January 1, 2004, were defined as exposed. We considered exposure as a time-varying parameter, and we used multivariable Cox regression models to estimate hazard ratios (HRs) of breast cancer. We performed a competing risk analysis using a cause-specific hazard approach to study the heterogeneity by tumour subtype/stage/grade. RESULTS: Among 62,512 postmenopausal women (median age at inclusion of 63 years old), 2864 developed breast cancer during a median follow-up of 9 years (between years 2004 and 2014). Compared with non-exposure, glucocorticoid exposure was not associated with overall breast cancer risk [HR = 0.94 (0.85-1.05)]; however, it was associated with a higher risk of in situ breast cancer and a lower risk of invasive breast cancer [HRinsitu = 1.34 (1.01-1.78); HRinvasive = 0.86 (0.76-0.97); Phomogeneity = 0.01]. Regarding the risk of invasive breast cancer, glucocorticoid exposure was inversely associated with oestrogen receptor (ER)-positive breast cancer [HRER+ = 0.82 (0.72-0.94); HRER- = 1.21 (0.88-1.66); Phomogeneity = 0.03]; it was also inversely associated with the risk of stage 1 or stage 2 tumours but positively associated with the risk of stage 3/4 breast cancers [HRstage1 = 0.87 (0.75-1.01); HRstage2 = 0.67 (0.52-0.86); HRstage3/4 = 1.49 (1.02-2.20); Phomogeneity = 0.01].

Published
2021

14. 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study

Author

Delaloge, S., primary, Dureau, S., additional, D'Hondt, V., additional, Desmoulins, I., additional, Heudel, P-E., additional, Duhoux, F., additional, Levy, C., additional, Lerebours, F., additional, Mouret-Reynier, M-A., additional, Dalenc, F., additional, Frenel, J-S., additional, Jouannaud, C., additional, Venat-Bouvet, L., additional, Nguyen, S., additional, Callens, C., additional, Gentien, D., additional, Manduzio, H., additional, Vincent-Salomon, A., additional, Lemonnier, J., additional, and Cottu, P.H., additional

Published
2021
Full Text
View/download PDF

15. 1710P International multicentric evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak

Author

Bizot, A., primary, Heudel, P-E., additional, Karimi, M., additional, Levy, C., additional, Vanlemmens, L., additional, Uzan, C., additional, Deluche, E., additional, Genet, D., additional, Saghatchian, M., additional, Giacchetti, S., additional, Grenier, J., additional, Patsouris, A., additional, Dieras, V.C., additional, Pierga, J-Y., additional, Petit, T., additional, Ladoire, S., additional, Jacot, W., additional, Delaloge, S., additional, Lambertini, M., additional, and Pistilli, B., additional

Published
2020
Full Text
View/download PDF

16. Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer

Author

Saleh, K., primary, Carton, M., additional, Dieras, V.C., additional, Heudel, P.-E., additional, Brain, E., additional, Firmin, N., additional, Mailliez, A., additional, Patsouris, A., additional, Mouret Reynier, M.A., additional, Gonçalves, A., additional, Ferrero, J.-M., additional, Petit, T., additional, Levy, C., additional, Uwer, L., additional, Cottu, P.H., additional, Veron, L., additional, Deluche, E., additional, Savignoni, A., additional, Robain, M., additional, and Delaloge, S., additional

Published
2019
Full Text
View/download PDF

18. Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse

Author

Ray-Coquard, I.L., primary, Harter, P., additional, Lorusso, D., additional, Dalban, C., additional, Vergote, I.B., additional, Fujiwara, K., additional, Gladieff, L., additional, Lueck, H.-J., additional, Floquet, A., additional, Lesoin, A.F., additional, Schnelzer, A., additional, Pignata, S., additional, Selle, F., additional, Sehouli, J., additional, Brocard, F., additional, Mangili, G., additional, Pautier, P., additional, De Giorgi, U., additional, Provansal, M., additional, and Heudel, P.-E., additional

Published
2018
Full Text
View/download PDF

19. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Author

Italiano, A., primary, Le Saux, O., additional, André, F., additional, Filleron, T., additional, Spaeth, D., additional, Heudel, P.-E., additional, Albiges, L., additional, Bachelot, T., additional, Gonçalves, A., additional, Pierga, J.-Y., additional, Barlesi, F., additional, Boige, V., additional, Lebbe, C., additional, Mortier, L., additional, Frenel, J.-S., additional, Tredan, O., additional, Jimenez, M., additional, Legrand, F., additional, and Ferté, C., additional

Published
2018
Full Text
View/download PDF

21. EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Author

Le Saux, O., primary, Italiano, A., additional, Spaeth, D., additional, Heudel, P.-E., additional, Filleron, T., additional, Pezzella, V., additional, Jimenez, M., additional, Legrand, F., additional, and Ferté, C., additional

Published
2018
Full Text
View/download PDF

22. Abstract P6-14-02: Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program

Author

Jacot, W, primary, Heudel, P-E, additional, Fraisse, J, additional, Gourgou, S, additional, Guiu, S, additional, Dalenc, F, additional, Pistilli, B, additional, Campone, M, additional, Levy, C, additional, Debled, M, additional, Leheurteur, M, additional, Chaix, M, additional, Lefeuvre, C, additional, Goncalves, A, additional, Uwer, L, additional, Ferrero, J-M, additional, Eymard, J-C, additional, Petit, T, additional, Mouret-Reynier, M-A, additional, Courtinard, C, additional, Cottu, P, additional, Robain, M, additional, and Mailliez, A, additional

Published
2018
Full Text
View/download PDF

23. Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study

Author

Selle, F., primary, Heudel, P-E., additional, Tazi, Y., additional, Pozet, A., additional, Hardy-Bessard, A-C., additional, Meunier, J., additional, Gladieff, L., additional, Lotz, J-P., additional, Provansal, M., additional, Augereau, P., additional, Frenel, J-S., additional, Bonichon-Lamichhane, N., additional, Orfeuvre, H., additional, Pommeret, F., additional, Torres-Macque, M., additional, Kalbacher, E., additional, and Roemer-Becuwe, C., additional

Published
2017
Full Text
View/download PDF

24. Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

Author

Cottu, P., primary, D'Hondt, V., additional, Dureau, S., additional, Lerebours, F., additional, Desmoulins, I., additional, Heudel, P-E., additional, Duhoux, F., additional, Levy, C., additional, Mouret-Reynier, M-A., additional, Dalenc, F., additional, Frenel, J-S., additional, Jouannaud, C., additional, Venat-Bouvet, L., additional, Nguyen, S., additional, Ferrero, J-M., additional, Canon, J-L., additional, Grenier, J., additional, Lemonnier, J., additional, Vincent-Salomon, A., additional, and Delaloge, S., additional

Published
2017
Full Text
View/download PDF

27. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

Author

Heudel, P-E, primary, Fabbro, M, additional, Roemer-Becuwe, C, additional, Kaminsky, M C, additional, Arnaud, A, additional, Joly, F, additional, Roche-Forestier, S, additional, Meunier, J, additional, Foa, C, additional, You, B, additional, Priou, F, additional, Tazi, Y, additional, Floquet, A, additional, Selle, F, additional, Berton-Rigaud, D, additional, Lesoin, A, additional, Kalbacher, E, additional, Lortholary, A, additional, Favier, L, additional, Treilleux, I, additional, and Ray-Coquard, I, additional

Published
2017
Full Text
View/download PDF

29. 182TiP - EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors

Author

Italiano, A., Le Saux, O., André, F., Filleron, T., Spaeth, D., Heudel, P.-E., Albiges, L., Bachelot, T., Gonçalves, A., Pierga, J.-Y., Barlesi, F., Boige, V., Lebbe, C., Mortier, L., Frenel, J.-S., Tredan, O., Jimenez, M., Legrand, F., and Ferté, C.

Published
2018
Full Text
View/download PDF

31. Abstract P1-08-06: SToRM: A prospective clinical trial of 1502 metastatic breast cancer (mBC) patients with detail of clinical presentation, molecular subtype, treatment modalities, prognosis and GWAS genotyping

Author

Bachelot, T, primary, Lavergne, E, additional, Romieu, G, additional, Rios, M, additional, Heudel, P-E, additional, Roemer-Becuwe, C, additional, Jouannaud, C, additional, Tredan, O, additional, Chaigneau, L, additional, Arnedos, M, additional, Orfeuvre, H, additional, Petit, T, additional, Quenel-Tueux, N, additional, Jacquin, J-P, additional, Ferrero, J-M, additional, Moullet, I, additional, Abadie-Lacourtoisie, S, additional, Penault-Llorca, F, additional, Blanc, E, additional, and Cox, D, additional

Published
2016
Full Text
View/download PDF

34. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy.

Author

Heudel, P. E., Devouassoux-Shisheboran, M., Taieb, S., Genestie, C., Selle, F., Morice, P., Rouzier, R., and Ray-Coquard, I.

Subjects
*OVARIAN cancer, *COMPUTED tomography, *CYTOREDUCTIVE surgery, *GYNECOLOGIC cancer, *INTERDISCIPLINARY research
Abstract

The management of advanced ovarian cancer generally requires specialist multidisciplinary teamwork to achieve optimum outcomes. Preoperative computed tomography scans are the imaging modality of choice in determining the extent of disease and aiding in surgical planning. Histological classification is crucial to define various subtypes with their different behaviour and prognosis and to plan the best therapeutic strategy. Pathological prognostic factors, such as histological type, degree of differentiation, and FIGO stage must be described. To determine the ability to optimally cytoreduce advanced ovarian cancer, an experienced gynaecological oncologist needs to explore the entire upper abdomen and the pelvic and para-aortic lymph node regions to define the peritoneal cancer index (PCI). The final assessment is the completeness of cytoreduction (CC) score which is important in predicting prognosis and decision of post-surgical surgery. Ovarian cancer is the leading cause of death from gynaecologic cancers. Initial management is best provided by a specialist multidisciplinary team, including a radiologist, a pathologist, a gynaecologic oncologist, and a medical oncologist. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

36. 578P Tertiary cancer prevention: A national evaluation of the practices and perceptions of hospital-based health care professionals (HHCPs) in charge of the follow-up (FU) care of cancer.

Author

Ben Ahmed, T., Veron, L., Dubois-Delaloge, E., Pudlarz, T., Abdayem, P., Vidican, P., Petureau, A., Schillinger, P., Caron, O., Bensen, A., Boucher, S., Khettab, M., Heudel, P-E., Bernard, E., Lefeuvre-Plesse, C., Fervers, B., Luis, I. Vaz, and Delaloge, S.

Subjects
*MEDICAL personnel, *CANCER prevention, *CANCER treatment
Published
2024
Full Text
View/download PDF

37. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Author

Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P. E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A. C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., N'Kodia, A., and Gilles-Afchain, L.

Subjects
*PLACEBOS, *CLINICAL trials, *CD4 antigen, *LYMPHOCYTES, *BREAST cancer patients
Abstract

Background: Lymphopenia is a predictive factor for hematological toxicity, progression and early death in advanced cancers including metastatic breast cancer (MBC). CYT107 is a recombinant interleukin 7 (IL-7) (Cytheris, now Revimmune), well tolerated and able to expand lymphocyte pool in humans. The aims of this study were to determine the optimal schedule to deliver CYT107 and to assess its effect on clinical end points. Patient and methods: This placebo-controlled, double blind, phase IIa was conducted in MBC patients with <1500/μl lymphocytes treated with capecitabine. Using a 2-by-2 factorial design, 20 patients were randomly allocated to four arms to receive (i) before chemotherapy: CYT107 or placebo; then (ii) during chemotherapy: CYT107 or placebo. The primary end point was CD4+ count changes before and during chemotherapy. Secondary end points were hematological toxicity, safety, overall response, progression-free survival (PFS) and overall survival (OS). Quantification and functional competence of circulating immune cells were also assessed. Results: When administered before chemotherapy, CYT107 induced a significant increase of CD4+ [+148.1% in CYT107 versus +9.9% in placebo groups, (Wilcoxon, P = 0.002)] and CD8+ T-cell counts, including both naïve and memory subsets. When CYT107 was administered during chemotherapy, the magnitude of CD4+ and CD8+ increase was less important. No modulation of immune cell functional competence was observed. CYT107 was well tolerated with no related ≥grade 3 adverse events except 1 fatal suspected unexpected serious adverse reaction (SUSAR) of uncertain relationship. Of the 12 cases evaluable for response, 6 of 7 patients (86%) receiving CYT107 before chemotherapy achieved a response or stabilization, whereas two of five patients (40%) receiving placebo achieved the same result. No significant difference was observed for PFS or OS. Conclusion: In lymphopenic MBC, CYT107 increases CD4+ and other T-cell subset counts without altering their function. A larger clinical trial to demonstrate its impact on clinical outcome is warranted. ClinicalTrials.gov Identifier: NCT01362107. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

39. Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors.

Author

Heudel PE, de Montfort A, Debieuvre D, Chouaid C, Carton M, Audigier-Valette C, Filleron T, Chabaud S, Stancu A, Quantin X, Hiret S, Bosquet L, and Blay JY

Subjects
Humans, Immune Checkpoint Inhibitors therapeutic use, Retrospective Studies, Propensity Score, Lung, Lung Neoplasms drug therapy, Lung Neoplasms epidemiology, Neoplasms, Second Primary
Abstract

Background: Lung cancer survivors are at high risk of developing a second primary cancer (SPC). We explored the Unicancer Epidemiology Strategy Medical-Economics for advanced or metastatic lung cancer (AMLC) database to assess the impact of immune checkpoint inhibitors (ICI) on the risk of SPC in patients with advanced/metastatic lung cancer., Patients and Methods: This retrospective study used data from patients with AMLC, with treatment initiated between January 1st 2015 and December 31st 2018. Patients with lung cancer as the second primary cancer were excluded and a 6-months landmark threshold was applied to exclude patients with synchronous SPC, patients dead without SPC or with a follow-up inferior to 6 months. A propensity score (PS) was calculated on the following baseline covariates: Age at locally advanced or metastatic diagnosis, sex, smoking status, metastatic status, performance status and histological type. The inverse probability of treatment weighting approach was used on the analyses aiming to assess the impact of ICI administered for AMLC, on the risk of occurrence of SPC., Results: Among the 10 796 patients, 148 (1.4%) patients had a diagnosis of SPC in a median interval of 22 (min-max: 7-173) months. All the patients (100%) with locally advanced or metastatic LC received at least one systemic treatment including (chemotherapy regimen (n = 9 851, 91.2%); ICI (n = 4 648, 43.0%); targeted treatment (n = 3 500; 32.4%). 40 (0.9%) SPC were reported in the 4 648 patients with metastatic LC treated with ICI vs 108 (1.7%) out of the 6 148 who did not receive immunotherapy (p < 0.0001). The multivariate analysis identified that treatment with ICI in patients with AMLC is associated with a reduced risk of SPC (HR = 0.40, 95% CI 0.27-0.58)., Conclusion: Treatment with ICI in AMLC patients was associated with a significantly reduced risk of SPC. Prospective studies are required to confirm these results., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results